Business Description
Healius Ltd
ISIN : AU0000033359
Share Class Description:
FRA:PGZ: Ordinary SharesTotal Employee Number:
8,000Description
Healius is Australia's second-largest pathology provider. Pathology revenue is almost entirely earned via the public health Medicare system and makes up the majority of Healius' group revenue. A small portion comes from its clinical testing business, Agilex.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | 0.31 | |||||
Debt-to-Equity | 1.69 | |||||
Debt-to-EBITDA | -2.82 | |||||
Interest Coverage | 1.63 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -1.87 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -20.3 | |||||
3-Year FCF Growth Rate | -26.8 | |||||
3-Year Book Growth Rate | -36.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.29 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.63 | |||||
9-Day RSI | 50.08 | |||||
14-Day RSI | 48.78 | |||||
3-1 Month Momentum % | -38.7 | |||||
6-1 Month Momentum % | -66.85 | |||||
12-1 Month Momentum % | -52.65 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.58 | |||||
Quick Ratio | 0.5 | |||||
Cash Ratio | 0.12 | |||||
Days Inventory | 55.88 | |||||
Days Sales Outstanding | 39.01 | |||||
Days Payable | 275.83 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.7 | |||||
Shareholder Yield % | 202.12 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.5 | |||||
Operating Margin % | 1.47 | |||||
Net Margin % | -12.32 | |||||
EBITDA Margin % | -24.32 | |||||
FCF Margin % | 9.18 | |||||
OCF Margin % | 13.72 | |||||
ROE % | -23.32 | |||||
ROA % | -7.65 | |||||
ROIC % | 0.9 | |||||
3-Year ROIIC % | 14.33 | |||||
ROC (Joel Greenblatt) % | -53.77 | |||||
ROCE % | -34.13 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 212 | |||||
Price-to-Owner-Earnings | 43.33 | |||||
PS Ratio | 0.2 | |||||
PB Ratio | 0.49 | |||||
Price-to-Tangible-Book | 3.5 | |||||
Price-to-Free-Cash-Flow | 2.17 | |||||
Price-to-Operating-Cash-Flow | 1.45 | |||||
EV-to-EBIT | -2.06 | |||||
EV-to-Forward-EBIT | 10.67 | |||||
EV-to-EBITDA | -3.49 | |||||
EV-to-Forward-EBITDA | 4.45 | |||||
EV-to-Revenue | 0.86 | |||||
EV-to-Forward-Revenue | 0.82 | |||||
EV-to-FCF | 9.32 | |||||
Price-to-GF-Value | 0.37 | |||||
Price-to-Projected-FCF | 0.09 | |||||
Price-to-Median-PS-Value | 0.19 | |||||
Earnings Yield (Greenblatt) % | -48.3 | |||||
FCF Yield % | 46.17 | |||||
Forward Rate of Return (Yacktman) % | 35.86 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Healius Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 775.358 | ||
| EPS (TTM) (€) | -0.131 | ||
| Beta | 0.9821 | ||
| 3-Year Sharpe Ratio | -1.3 | ||
| 3-Year Sortino Ratio | -1.37 | ||
| Volatility % | 55.26 | ||
| 14-Day RSI | 48.78 | ||
| 14-Day ATR (€) | 0.009868 | ||
| 20-Day SMA (€) | 0.20765 | ||
| 12-1 Month Momentum % | -52.65 | ||
| 52-Week Range (€) | 0.17 - 0.615 | ||
| Shares Outstanding (Mil) | 726.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Healius Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Healius Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-10-30 11:00 | In 119 days | ||
| Annual report for 2026 | 2026-09-25 | In 83 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-08-21 11:30 | In 49 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-21 | In 48 days | ||
| Second quarter earnings conference call for 2026 | 2026-02-18 10:30 | 0.47 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-02-18 | 0.47 (+0.00%) | ||
| General meeting for 2025 | 2025-10-30 11:00 | 0.44 (+0.00%) | ||
| Annual report for 2025 | 2025-09-26 | 0.41 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2025-08-21 11:30 | 0.42 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-21 | 0.42 (+0.00%) |
Show
Entries
Healius Ltd Frequently Asked Questions
What is Healius Ltd(FRA:PGZ)'s stock price today?
The current price of FRA:PGZ is €0.21. The 52 week high of FRA:PGZ is €0.62 and 52 week low is €0.17.
When is next earnings date of Healius Ltd(FRA:PGZ)?
The next earnings date of Healius Ltd(FRA:PGZ) is 2026-08-21 Est..
Does Healius Ltd(FRA:PGZ) pay dividends? If so, how much?
Healius Ltd(FRA:PGZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Healius Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers